AMP Starts Position in Anthera Pharmaceuticals


Today AMP started a position in Anthera Pharmaceuticals (ANTH) by purchasing 14,792 shares at $1.69/share in a transaction totaling ~$25K.

Anthera Pharmaceuticals is a clinical stage company developing two clinical assets: Sollpura the first non-pig derived pancreatic enzyme replacement therapy (PERT) for patients with cystic fibrosis and endocrine pancreatic insufficiency and Blisibimod for treatment of IgA nephropathy (IgAN).


*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

PROUDLY CREATED WITH WIX.COM

  • Twitter Social Icon
  • LinkedIn Social Icon